BIBLIOGRAFIA

Âncora 2

[1] Saeed MA, Narendran P. 2014. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Design, Development Therapy, 8:2493-2505

[2] Brunton SA. 2015. The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. International journal of clinical practice, 69(10): 1071-1087

[3] Bailey CJ, Aschner P, Del Prato S, et al. 2013. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diabetes and Vascular Disease Research Journal, 10: 397–409

[4] Shyangdan DS, Uthman OA, Waugh N. 2016. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ open, 6(2), e009417

[5] List JF, Woo V, Morales E, Tang W & Fiedorek FT. 2009. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 32(4): 650-657

[6] Committee for Medicinal Products for Human Use (CHMP). 2012. Forxiga Dapagliflozin assessment report. European Medicines Agency, EMA/689976. Disponível em http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf

[7] Filippatos TD, Liberopoulos EM & Elisaf MS. 2014. Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic advances in endocrinology and metabolism, 6(1): 29-41

[8] Liakos A, Karagiannis T, Bekiari E, Boura P & Tsapas A. 2014. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic advances in endocrinology and metabolism, 6(2): 61-67

[9] Sonesson C, Johansson PA, Johnsson E & Gause-Nilsson I. 2016. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular diabetology, 15(1): 1

[10] DeFronzo RA, Hompesch M, Kasichayanula S, et al. 2013. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care, 36(10): 3169–3176

[11] Risco de cetoacidose diabética, comunicação aos profissionais de saúde. Julho de 2015. INFARMED disponível em http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/FARMACOVIGILANCIA/INFORMACAO_SEGURANCA/CARTAS_PROFISSIONAIS/F_J/Inibidore_SGLT2_versaofinal_julho2015.pdf

[12] Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S & Johnsson E. 2016. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis. Diabetes Therapy, 7: 125-137

[13] Mattu A, Brady WJ, Robinson DA. 2000. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med, 18: 721–9

[14] Schwartz SS & Katz A. 2016. Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 9: 71